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Results from the DOLAB study.
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Introduction
Good sleep quality and duration are essential for children’s
learning and behaviour.
Past research
Fatty acid (LC-PUFA) metabolites play a role in sleep
regulation and fatty acid supplementation may reduce anxiety
effects of sleep deprivation.
However, little is known about the effect of the LC-PUFA
DHA Omega-3 on sleep in children.
Research Question
•Does supplementation with DHA Omega-3 change the qual-
ity, duration and timing of children’s sleep.
Methods
The DHA Oxford Learning and Behaviour Study (Dolab) is
a randomized, double-blind, placebo-controlled trial.
Participants
Children aged 7-9 from mainstream schools, underperforming
in literacy skills according to nationally standardised assess-
ments (KS1) were invited. NHS ethics as well as parental
consent and child assent was obtained.
Children invited from 74 Oxfordshire (UK) schools:
n = 1376
Parents did not consent (n=701)
Parent consent:
n=675
Did not meet inclusion criteria (n=313):
BAS Reading≤33% (n =236 );
Eating Fish ≥ 2x week (n= 50)
Already taking Omega-3 (n=9);
Sibling in study (n=8); Capsule refusal (n=5);
Moderate Learning Difficulty (n=3);
Medication (n=2)
Randomization sample
Assessment of Subjective Sleep (CSHQ)
n=362
Actigraphy subsample
n=43
(randomly selected)
Actigraph not worn (n=2)
Baseline
(Active n=180, Placebo n=182)
Actigraphy Baseline
(Active n=19, Placebo n=24)
Actigraph not worn (n=9)
Postintervention
(Active n=179, Placebo n=180)
Children moved out of area (n=3)
Actigraphy Postintervention
(Active n=15, Placebo n=19)
Intervention
Supplementation with DHA (600mg/day for 16 weeks) with a
control group receiving a soy/corn oil placebo.
Outcomes
1. Subjective sleep: Measured using the Child Sleep
Health Questionnaire, with eight sub-scales and one total
sleep disturbance score.
2.Objective sleep: Children in a subsample (15%) were
assessed using an actigraph during five consecutive nights
at baseline and follow-up.
(More details in separate box Actigraphy).
Improvements in Objective Sleep (Actigraphy)
Following Supplementation with DHA Omega-3
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Means Pre−/Post−Intervention
Total Minutes of Sleep & Wakefulness per Night
On average, children who received DHA during the 16-week
intervention, compared to those who did not:
• Spent 44min less awake during an average night.
•Got 58min more sleep per night.
Change in Sleep Efficiency & Number of
Night-wakings
9% efficiency gain
1%
Sig. difference: p<.052
approx. 10 wakings less
−3.5
Sig. difference: p<.013
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Sleep Efficency and Number of Wake−episodes
In addition, children in the intervention group, compared to
the placebo group:
•Gained 8% sleep efficiency (sleep during time in bed).
•Had 7 fewer wake episodes per night, (brief wakings).
Supplementation, Subjective Sleep (CSHQ) and Clinical Relevance
Change in Subjective Sleep (CSHQ)
following Supplementation
p<.318 p<.478 p<.469 p<.245 p<.849 p<.196 p<.816 p<.898 p<.495
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Change Scores for CSHQ
The Child Health Questionaire (CSHQ) measures subjective
sleep quality.
A “Total Sleep Disturbance” score >41 is used to diagnose
clinical sleep problems.
No significant improvements in parents’ perceptions of sleep
were found across the subscales of the CSHQ.
Improvements in a Clinical Subgroup of
children with sleep problems
p<.526 p<.871 p<.129 p<.366 p<.668 p<.039 p<.817 p<.753 p<.05.5
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CSHQ Clinical Subgroup − Effects of Supplementation
A post-hoc analysis of children with clinical sleep problems
shows some improvements.
Total Sleep Disturbance: Children had significantly
lower scores if they received the DHA supplement.
Parasomnia: Parents of children in the active group men-
tioned fewer parasomnias (e.g. sleepwalking).
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Actigraphy: How to measure
sleep objectively?
MicroMini-Motionlogger R©, Ambulatory Monitoring Inc.
What is an
Actigraph?
Actigraphs are small,
watch-sized movement
sensors, worn on the
wrist or ankle (see pic-
ture).
How do Actigraphs
work?
Actigraphy assesses sleep
by measuring movement
during time in bed.
A sensor logs the
frequency and pattern
of movement, which
allows the detection of
basic sleep-wake pat-
terns.
How well does Actigraphy measure sleep?
Actigraphy sleep measures correlate with the best measures
of sleep from clinical polysomnography to about 80%.
Conclusions
Results:
The analyses of subjective and objective sleep as secondary
outcomes of the Dolab Study suggest that:
• DHA supplementation improves the quality
of child sleep.
Children taking DHA had less wake episodes per night
and received on average 58mins more sleep.
After supplementation children and gained 8% sleep
efficiency.
Relevance:
Post-hoc analyses suggest that with regard to subjective
sleep:
•Children with clinical sleep problems might
particularly benefit from DHA supplementa-
tion.
Future Research:
These exploratory analyses give good grounds for future
research into LC-PUFA as a cheap and safe treatment for
sleep problems.
•Future studies should focus on children with
poor sleep outcomes as these might benefit
most.
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